A novel systemic inflammation response index (SIRI) for predicting postoperative survival of patients with endometrial cancer

Abstract Background Systemic Inflammation Response Index (SIRI) has been reported as an effective biomarker to predict prognosis in various cancers. However, the prognostic value of SIRI in endometrial cancer remains unclear. This study aimed to investigate the potential prognostic significance of SIRI in patients with endometrial cancer. Methods A total of 586 patients with endometrial cancer who underwent radical surgical treatment was retrospectively recruited from the First Affiliated Hospital of Chongqing Medical University. Univariate and multivariate analysis were used to select parameters related to recurrence of patients with endometrial cancer. The optimal threshold of SIRI was assessed by receiver operating characteristic curve. Patients were divided into low-SIRI and high-SIRI groups according to the optimal SIRI cut-off value. The differences of clinicopathological parameters and survival analysis between the low-SIRI and high-SIRI groups were compared. Results Multivariate analysis indicated that SIRI was an independent predictor for recurrence and death of endometrial cancer. The optimal threshold of SIRI for predicting recurrence and death of endometrial cancer was 1.29. Endometrial cancer patients in low-SIRI group had better prognosis than those in the high-SIRI group (P < 0.001). Among the 231 patients without adjuvant therapy, patients in the low-SIRI group had longer recurrence-free survival and overall survival than those in the high- SIRI group (P = 0.004, P = 0.003). Conclusions SIRI was identified as an independent prognostic factor for endometrial cancer. Endometrial cancer patients with higher SIRI had a worse prognosis. High-SIRI could be a prognostic stratification factor for endometrial patients.